Author:
Li Yuezhe,Wilkins A. Katharina,Davis Jimena,Knab Timothy,Toukam Marie,Boni Joseph P.,Kirouac Daniel C.
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Scott, E. C. et al. Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nat. Rev. Drug Discov. 22, 625–640 (2023).
2. Tang, L., Huang, Z., Mei, H. & Hu, Y. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduct. Target. Ther. 8, 306 (2023).
3. Dotan, E., Aggarwal, C. & Smith, M. R. Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin’s lymphoma. P T 35, 148–157 (2010).
4. Meng, F., Zhong, D., Zhang, L., Shao, Y. & Ma, Q. Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis. Int. J. Clin. Exp. Med. 8, 17515–17522 (2015).
5. Song, F. et al. Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL. J. Immunother. Cancer 11, e005701 (2023).